[1] 金宇,刘晓玲,黄怡丹. 免疫球蛋白和自身抗体在乙型肝炎肝硬化发病和进展中的表达及与预后的关系[J]. 中国现代医学杂志,2023,33(4):56-61. [2] 苏小红,李静博. 肝硬化患者血小板参数、凝血指标与上消化道出血的相关性[J]. 肝脏,2023,28(10):1171-1174. [3] Ho P T B, Clark I M, Le L T T. MicroRNA-based diagnosis and therapy[J]. Int J Mol Sci, 2022, 23(13): 7167. [4] Wu Y, Li Q, Zhang R, et al. Circulating microRNAs: Biomarkers of disease[J]. Clinica Chimica Acta, 2021, 516: 46-54. [5] Hsu S, Wang B, Kota J, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver[J]. JCI, 2012, 122(8): 2871-2883. [6] Thakral S, Ghoshal K. miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir[J]. Curr Gene Ther, 2015, 15(2): 142-150. [7] Hayes C N, Chayama K. MicroRNAs as biomarkers for liver disease and hepatocellular carcinoma[J]. Int J Mol Sci, 2016, 17(3): 280. [8] Li A, Wu J, Zhai A, et al. HBV triggers APOBEC2 expression through miR122 regulation and affects the proliferation of liver cancer cells[J]. Int J Oncol, 2019, 55(5): 1137-1148. [9] Ucar F, Sezer S, Ginis Z, et al. APRI, the FIB-4 score, and Forn’s index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B[J]. Eur J Gastroen Hepat, 2013, 25(9): 1076-1081. [10] Scheuer PJ, Maggi G. Hepatic fibrosis and collapse: histological distinction by orcein staining[J]. Histopathology, 1980, 4(5): 487-490. [11] 沈镇扬,陆伦根. 肝纤维化治疗靶点的发现与验证[J]. 肝脏,2022,27(7):737-739. [12] Berumen J, Baglieri J, Kisseleva T, et al. Liver fibrosis: Pathophysiology and clinical implications[J]. WIRES?Mech Dis, 2021, 13(1): e1499. [13] Ahodantin J, Lekbaby B, Bou Nader M, et al. Hepatitis B virus X protein enhances the development of liver fibrosis and the expression of genes associated with epithelial-mesenchymal transitions and tumor progenitor cells[J]. Carcinogenesis, 2020, 41(3): 358-367. [14] Tan Z, Sun H, Xue T, et al. Liver fibrosis: therapeutic targets and advances in drug therapy[J]. Front Cell Dev Biol, 2021, 9: 730176. [15] Guixe-Muntet S, Zhu CP, Xie WF, et al. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease[J]. Pharmacology & therapeutics, 2020, 215: 107626. [16] Wang X, He Y, Mackowiak B, et al. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases[J]. Gut, 2021, 70(4): 784-795. [17] Cardoso A P F, Udoh KT, States JC. Arsenic-induced changes in miRNA expression in cancer and other diseases[J]. TAAP, 2020, 409: 115306. [18] Schueller F, Roy S, Vucur M, et al. The role of miRNAs in the pathophysiology of liver diseases and toxicity[J]. Int J Mol Sci, 2018, 19(1): 261. [19] Xu L, Li T, Ding W, et al. Combined seven miRNAs for early hepatocellular carcinoma detection with chronic low-dose exposure to microcystin-LR in mice[J]. Sci Total Environ, 2018, 628: 271-281. [20] Fang Q, Chen W, Jian Y, et al. Serum expression level of MicroRNA-122 and its significance in patients with hepatitis B virus infection[J]. J Healthc Eng, 2022, 2022. [21] Halász T, Horváth G, Pár G, et al. miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan[J]. World J Gastroenterol, 2015, 21(25): 7814. [22] 王燕,陈香宇,李娅,等. 血清微小核糖核酸-122在慢性乙型肝炎肝纤维化中的表达及意义[J]. 中华传染病杂志,2018,36(9):533-536. |